bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
Company profile
Website
CEO
Nick Leschly
Employees
Location
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943319751
Latest filings (excl ownership)
15-12G
Securities registration termination
13 May 05
8-K
Regulation FD Disclosure
11 May 05
DEFM14A
Proxy related to merger
8 Apr 05
10-K
2004 FY
Annual report
30 Mar 05
PREM14A
Preliminary proxy related to merger
28 Mar 05
8-K
Entry into a Material Definitive Agreement
4 Mar 05
DEFA14A
Additional proxy soliciting materials
1 Mar 05
DEFA14A
Additional proxy soliciting materials
1 Mar 05
8-K
Entry into a Material Definitive Agreement
25 Feb 05
8-K/A
Results of Operations and Financial Condition
17 Feb 05
Latest ownership filings
No filings